PTSD Susceptibility and Challenges: Pathophysiological Consequences of Behavioral Symptoms

Area of Science:

• Neuroscience
• Immunology
• Biochemistry

Background:

• Posttraumatic stress disorder (PTSD) affects millions, particularly military personnel, often stemming from traumatic events.
• Blood-brain barrier disruptions can trigger neuroinflammation and alter brain function, leading to behavioral changes associated with PTSD.
• Current diagnostic methods like MRI/fMRI may not detect early or subclinical PTSD symptoms.

Purpose of the Study:

• To identify potential plasma-based neural biomarkers for PTSD in veterans.
• To compare protein and cytokine levels between veterans with PTSD and healthy controls.
• To investigate the role of matrix metalloproteinases (MMPs) in PTSD pathophysiology.

Main Methods:

• Enzyme-linked immunosorbent assay/immunofluorometric sandwich assay used to measure neurotrophic factors and cytokines.
• Zymography employed to assess the catalytic activity of matrix metalloproteinases (MMPs).
• Plasma samples from 20 PTSD veterans were compared to age-matched healthy veteran controls.

Main Results:

• Increased levels of glial fibrillary acidic protein, tumor necrosis factor-alpha, interleukin 6, MMP2, and MMP9 were observed in PTSD veterans.
• Decreased levels of brain-derived neurotrophic factor and nerve growth factor-beta were noted.
• S100 calcium-binding protein B showed no significant difference between groups.

Conclusions:

• The identified proteins and cytokines represent potential diagnostic biomarkers for PTSD.
• These biomarkers could facilitate earlier detection of PTSD, even before clinical manifestation or detection by neuroimaging.
• Further research is needed to validate these findings and explore their clinical utility in PTSD diagnosis and management.